Study of the targetting distribution of epirubicin polybutylcyanoacrylate magnetic nanoparticles in rat hepatic
Jinzhu Wu,Weihua Cai,Renfei Zhu,Zhihua Dou,Jianguo Shao,Jianxin Wang
DOI: https://doi.org/10.3877/cma.j.issn.1674-3946.2016.06.025
2016-01-01
Abstract:Objective To prepare and characterize epirubicin polybutylcyanoacrylate magnetic nanoparticles ( EPI-PBCA-MNPS) , and to offer a new dosage form of high-performance for targeted therapy of hepatoma, with further analyzing the distribution of the drug in rat liver . Methods Based on EPI-PB-CA-NPS research foundation , EPI-PBCA-MNPS was prepared by a reversed-phase micro-emulsion polymeri-zation method , of which reactive condition was correlatively characterized .The SD male rats were randomly divided into three groups:EPI (A)group; EPI-PBCA-MNPS(B) group; the external magnetic field (C) group, and is further divided into two sub-groups.The determination of plasma concentration of epirubicin:Cnon-targeted liver group and determination of liver tissue concentration of epirubicin :Ctargeted liver group through the tail vein injection with 15 rats in each group .The targeted distribution was analyzed .P<0.05 was thought to be statistically significant . Results EPI-PBCA-MNPS was uniformly and stably distributed in the colloid solution with the mean particle diameter of 151.3 ±29.6 nm.The mean envelopment rate , drug-loading, saturated magnetization intensity is 80.26 ±14.22%, 14.64 ±2.13%, 0.34 KA/m, respectively .After Tail vein injection , EPI concentration was significantly increased in the liver .The peak ahead of the drug was about 5min, with significantly reduced the EPI distribution in the spleen .The aggregation degree of liver was significantly enhanced .The accumulation of epirubicin in Ctargeted liver group was significantly higher by using an external magnetic field when compared to the Cnon -targeted liver group, A group and B group (P<0.05). Conclusion EPI-PBCA-MNPS had good magnetic response. An extraorgan magnetic field can significantly increase the accumulation of pharmorubicin in target liver , reducing the accumulation in other non-target organs .